Navigation Links
Vermillion Appoints Dr. Eric Varma to its Board of Directors

AUSTIN, Texas, Sept. 16, 2013 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, today announced the appointment of Eric Varma, M.D. to its board of directors.

"As a partner at Oracle Investment Management, Vermillion's largest shareholder, and a physician, Eric brings significant financial and commercial experience in the life sciences to our board of directors," said Thomas McLain, Vermillion's president and CEO. "His expertise will help guide the company as it continues to focus on its novel, high-value diagnostic test, OVA1® and improving the care for women with gynecological cancers."

Dr. Varma is currently a partner at Oracle Investment Management, which is a fundamental research driven investment management company that is exclusively focused on the global health care and bioscience industries. Prior to joining Oracle Investment Management, he worked at Leerink Swann, the Boston Consulting Group, and the Food and Drug Administration. Dr. Varma received his B.A. from the University of California Berkeley, M.D. from the Albert Einstein College of Medicine, and M.B.A. from the MIT Sloan School of Management.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit

Forward-Looking Statement
Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion has sufficient cash resources to fully commercialize its tests and continue as a going concern; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at

Investor Relations Contact:
Liolios Group, Inc.
Ron Both
Tel 1-949-574-3860

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
2. Vermillion Sets First Quarter 2013 Conference Call for Wednesday, May 15, 2013
3. Vermillion Appoints Thomas McLain as President and Chief Executive Officer
4. Vermillion Reports Fourth Quarter and Full Year 2012 Results
5. Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year 2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
6. Gynecologic Oncology Publishes New Clinical Study Showing Positive Performance of OVA1, Vermillions Ovarian Cancer Test
7. Vermillion Appoints Bruce A. Huebner as Interim Chief Executive Officer
8. Delaware Court of Chancery Dismisses Vermillion Dissident Shareholder Suit with Prejudice
9. Vermillion Reports Third Quarter 2012 Results
10. Vermillion Sets Third Quarter 2012 Conference Call for Monday, November 12, 2012 at 4:30 p.m. ET
11. Vermillion to Present at the 2012 Gateway Conference on September 6
Post Your Comments:
(Date:11/27/2015)... NEW YORK , November 27, 2015 ... health system is set to go online. The potential ... and processes is vast and far from fully exploited ... access to patient health records, either via mobile tablet ... ) --> ) ...
(Date:11/27/2015)... , Nov. 27, 2015 Research and ... the "Global Intrauterine Devices Market 2015-2019" report ... --> In this report, the author the ... devices market for 2015-2019. To calculate the market size, ... following type of products: Hormonal IUDs and copper IUDs. ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
Breaking Medicine Technology:
(Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
(Date:11/30/2015)... ... 30, 2015 , ... TransPack Volume 6 features 30 customizable transitions created exclusively ... transitions to wipes with blur & drop shadow options. Utilize the controls in ... one clip to the next with TransPack's easily customizable styles. , TransPack ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... to announce their strategic partnership at the Radiological Society of North America ... Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced their ...
(Date:11/30/2015)... ... November 30, 2015 , ... Several significant coding-related changes are ... likely to include new codes for spine and hip X-rays, paravertebral facet blocks ... of code changes in musculoskeletal, radiology and nervous system sections on an Orthopedic ...
Breaking Medicine News(10 mins):